US Multiomics Market (2026-2031)
The US Multiomics Market was valued at $1057 Million in 2026 and projected to reach to $1874.2 Million by 2031, representing a compound annual growth rate of 12.1%. The US multiomics market is poised for sustained expansion as healthcare systems prioritize precision medicine and shift toward data-driven clinical decision-making.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
US Multiomics Market Trends and Insights
- This expansion reflects the US healthcare sector's increasing adoption of integrated genomic, proteomic, and metabolomic technologies for precision medicine and personalized treatment strategies.
- The US market benefits from advanced research infrastructure, substantial healthcare investment, and a strong regulatory framework supporting innovation in multiomics platforms. Driving this growth, the US multiomics market is fueled by rising demand for comprehensive biomarker discovery, improved diagnostic accuracy, and the integration of artificial intelligence in data analysis.
- US pharmaceutical and biotechnology companies are increasingly leveraging multiomics approaches to accelerate drug development and reduce time-to-market.
- The 12.1% compound annual growth rate (CAGR) through 2031 underscores the US market's position as a global leader in adopting cutting-edge omics technologies. The US multiomics landscape is characterized by significant investment in clinical applications, including oncology, cardiovascular disease, and rare genetic disorders.
- Healthcare providers and research institutions across the US are prioritizing multiomics integration to enhance patient outcomes and enable data-driven clinical decision-making..
Key Market Statistics
- CAGR (2026-2031) 12.1% CAGR
- Market Size, 2026 ~USD 1057 Million
- Forecast, 2031 ~USD 1874.2 Million
- Country US
US Multiomics Market Overview
Market Valuation Growth :
The US multiomics market is valued at $1,057.0 million in 2026 and is projected to reach $1,874.2 million by 2031, representing a robust 12.1% CAGR over the forecast period.
Precision Medicine Adoption :
US healthcare providers are increasingly integrating genomic, proteomic, and metabolomic technologies to enable precision medicine and personalized treatment strategies across oncology, cardiology, and rare disease management.
Advanced Research Infrastructure :
The US benefits from world-class research institutions, well-established biotech ecosystems, and significant government funding through NIH and NSF, accelerating multiomics technology development and clinical adoption.
Regulatory Support & Innovation :
FDA initiatives supporting companion diagnostics and personalized medicine, combined with strong venture capital investment, are driving rapid commercialization of multiomics solutions in the US market.
US Multiomics Market Dynamics
- Increasing investments in genomic sequencing infrastructure, coupled with declining costs of multiomics technologies, are making integrated analysis more accessible to hospitals and diagnostic laboratories nationwide.
- The convergence of artificial intelligence with multiomics data is enabling deeper insights into disease mechanisms and treatment responses.
- Regulatory frameworks supporting companion diagnostics and personalized medicine are further accelerating market penetration across major therapeutic areas including oncology, cardiovascular disease, and immunology..
Market Ecosystem
MULTIOMICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Provides Illumina Connected Multiomics, a cloud-based platform that integrates and analyzes genomics, transcriptomics, proteomics, epigenomics, and other multiomic datasets. For example, oncology researchers at the University of Colorado Anschutz Medical Campus used the platform to analyze proteomic data and generate insights into melanoma biology. | Enables integrated analysis of multiple biological data layers, helping researchers identify biomarkers, understand disease mechanisms, and accelerate precision medicine and drug discovery. (Illumina) |
 |
Provides Chromium Single Cell Multiome ATAC + Gene Expression technology, enabling simultaneous profiling of chromatin accessibility and gene expression in individual cells. Its platforms are widely used in cancer, immunology, and developmental biology research to characterize cellular states and regulatory mechanisms. | Provides a comprehensive view of gene regulation at single-cell resolution, helping researchers link regulatory elements with gene expression and identify disease-associated cell populations. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- The US multiomics market will grow from $1,057.0M in 2026 to $1,874.2M by 2031, representing a 12.1% CAGR.
- US healthcare providers are increasingly adopting multiomics for precision medicine, biomarker discovery, and personalized treatment strategies.
- AI integration and advanced data analytics are accelerating multiomics adoption across US pharmaceutical and biotechnology sectors.
- Clinical applications in oncology, cardiovascular disease, and rare genetic disorders are primary growth drivers in the US market.
Multiomics Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | SERVICES (Offering) |
| Forecast Period | 2026-2031 |
| Growth Rate | CAGR of 12.3% from 2026 to 2031 |
| Largest Segment | PRODUCTS (Offering) |
| Market Size Base Year (Billions) | ~USD 3.19 (2026) |
| Revenue Forecast (Billions) | ~USD 5.7 (2031) |
| Segments Covered | Offering, Type, Technology, Method, Workflow, Application, End User |
US Multiomics Market Report Segmentation
7 segment dimensions are covered across the global market.
By Offering
- Products
- Services
By Type
- Assay Kits & Reagents
- Consumables
- Instruments & Software
- Long-Read Sequencing
- Ms-Based Proteomics
- Nanopore Sequencing
- Ngs-Based Proteomics
- Other Consumables
- Other Proteomics Methods
- Other Sequencing Technologies
- Pcr-Based Proteomics
- Smrt Sequencing
By Technology
- Long-Read Sequencing
- Nanopore Sequencing
- Other Sequencing Technologies
- Other Technologies
- Proteomics
- Sequencing
- Smrt Sequencing
By Method
- Chromatin Accessibility Sequencing
- Chromatin Interaction Analysis
- Dna Methylation Sequencing
- Epigenomics
- Histone Modification Profiling
- Long-Range Sequencing
- Long-Read & Long-Range Sequencing
- Long-Read Sequencing
- Ms-Based Proteomics
- Ngs-Based Proteomics
- Other Epigenomics Methods
- Other Long-Read & Long-Range Sequencing Methods
- Other Methods
- Other Proteomics Methods
- Other Single-Cell Omics
- Other Spatial Omics
- Pcr-Based Proteomics
- Proteomics
- Sequencing-Based Epigenomics
- Single-Cell Epigenomics
- Single-Cell Genomics
- Single-Cell Omics
- Single-Cell Proteomics
- Single-Cell Transcriptomics
- Spatial Epigenomics
- Spatial Genomics
- Spatial Omics
- Spatial Proteomics
- Spatial Transcriptomics
By Workflow
- Data Visualization & Analysis
- Sample Preparation
- Sequencing & Analysis/ Sample Characterization
- Sequencing & Analysis/Sample Characterization
By Application
- Biomarker Discovery
- Cell Biology
- Clinical Diagnostics
- Drug Discovery & Development
- Immunology
- Neurology
- Oncology
- Other Applications
- Precision Medicine
- Translational Research
By End User
- Academic & Research Institutes
- Cros & Cdmos
- Hospitals & Diagnostic/Clinical Laboratories
- Pharmaceutical & Biotechnology Companies
Target Audience
- Multiomics Technology Providers : Companies developing genomic, proteomic, and metabolomic platforms need US market intelligence to benchmark growth rates, identify market gaps, and develop targeted commercialization strategies for the $1.87B opportunity by 2031.
- Healthcare Systems & Hospitals : US hospital networks and integrated delivery systems require market data to evaluate multiomics technology investments, assess clinical ROI, and plan precision medicine program implementations aligned with market trends.
- Diagnostic Laboratory Operators : Clinical and reference laboratories need insights into US market demand, reimbursement trends, and competitive positioning to guide service expansion, technology adoption, and test menu development decisions.
- Pharmaceutical & Biotech Companies : Drug developers and biotech firms require US multiomics market data to inform companion diagnostic strategies, patient stratification approaches, and precision medicine clinical trial designs for regulatory approval.
- Investment & Private Equity Firms : Investors evaluating multiomics sector opportunities need comprehensive US market analysis, growth projections, and competitive dynamics to identify acquisition targets and assess portfolio company valuations.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise US market valuation ($1,057M in 2026) and 5-year forecast data to validate investment decisions, business expansion plans, and competitive positioning in the rapidly growing multiomics sector.
- US-Specific Regulatory Insights : Understand FDA approval pathways, companion diagnostic regulations, and reimbursement landscape specific to the US market to accelerate product commercialization and market entry strategies.
- Competitive Landscape Analysis : Identify key US players, market consolidation trends, and emerging competitors in multiomics to inform partnership strategies, M&A opportunities, and differentiation approaches.
- Clinical Adoption Drivers : Analyze US healthcare provider adoption patterns, hospital integration strategies, and clinical utility drivers to optimize go-to-market strategies and customer acquisition in key therapeutic areas.
- Investment & Funding Trends : Access data on venture capital flows, government funding initiatives, and strategic investments in US multiomics companies to identify growth opportunities and funding landscape dynamics.
Frequently asked questions
What is the current size of the US multiomics market in 2026?
The US multiomics market is valued at $1,057.0 million in 2026, reflecting strong adoption of integrated omics technologies across healthcare and research sectors.
What is the projected size of the US multiomics market by 2031?
The US multiomics market is projected to reach $1,874.2 million by 2031, growing at a compound annual growth rate of 12.1%.
What are the primary drivers of growth in the US multiomics market?
Key growth drivers include rising demand for precision medicine, increased biomarker discovery initiatives, AI-powered data analysis, and expanding clinical applications in oncology and rare diseases across the US.
Which therapeutic areas are leading multiomics adoption in the US?
Oncology, cardiovascular disease, and rare genetic disorders are the primary therapeutic areas driving multiomics adoption and investment in the US healthcare system.
How is artificial intelligence impacting the US multiomics market?
AI integration is accelerating multiomics data analysis, enabling faster biomarker identification, and improving clinical decision-making, thereby driving market expansion across US pharmaceutical and healthcare organizations.
RESEARCH METHODOLOGY
This study involved four major activities in estimating the current size of the multiomics market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), European Bioinformatics Institute (EMBL-EBI), US Food and Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO), and Organisation for Economic Co-operation and Development (OECD). Omics-specific repositories and research initiatives, including Human Protein Atlas, the Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Clinical Proteomic Tumor Analysis Consortium (CPTAC), among several others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global Multiomics market, and the findings were validated through primary research.
Primary Research
In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the multiomics market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Multiomics Market : Top-Down and Bottom-Up Approach
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.
Market Definition
The multiomics market comprises commercial revenues generated from products and services used to perform integrated multiomics analyses by combining two or more molecular profiling modalities, such as genomics, epigenomics, transcriptomics, proteomics, and spatial or single-cell omics. The market includes instruments, software, assay kits, reagents, consumables, and analytical services supporting advanced multiomics workflows from sample preparation and molecular characterization to data integration, visualization, and interpretation. These technologies are used across research and clinical applications, including oncology, precision medicine, biomarker discovery, translational research, drug discovery, and clinical diagnostics, by pharmaceutical and biotechnology companies, academic and research institutions, hospitals, diagnostic laboratories, CROs, and CDMOs. The market excludes conventional single-omics technologies, routine short-read sequencing workflows, microarray-based molecular profiling, and general laboratory products not specifically designed for integrated multiomics applications.
Key Stakeholders
- Multiomics product & service providers
- Multiomics bioinformatics/data analysis companies
- Venture capitalists and other government funding organizations
- Research and consulting firms
- Hospitals and diagnostic clinics
- Pharmaceutical and biotechnology companies
- Academic and government research institutes
- Life science companies
Report Objectives
- To define, describe, and forecast the multiomics market by offering, method, technology, workflow, application, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall multiomics market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC Countries (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC Countries) and the Rest of Middle East], and Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the Rest of Europe multiomics market, by country
- Further breakdown of the Rest of Asia Pacific multiomics market, by country
Company Analysis
- Detailed analysis and profiling of additional market players (up to five)
Segment Analysis
- Cross-segment analysis
Get the Full Multiomics Market Report
Full forecast, segment splits, and company analysis for all Multiomics Market.
- Canada Multiomics Market
- Germany Multiomics Market
- UK Multiomics Market
- France Multiomics Market
- Italy Multiomics Market
- Spain Multiomics Market
- China Multiomics Market
- Japan Multiomics Market
- South Korea Multiomics Market
- India Multiomics Market
- Australia Multiomics Market
- Brazil Multiomics Market
- Saudi Arabia Multiomics Market
- UAE Multiomics Market
- Rest Of Europe Multiomics Market
- Rest Of Asia Pacific Multiomics Market
- Rest Of Latin America Multiomics Market
- Rest Of GCC Countries Multiomics Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
